# Vicente Valero

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vicente-valero/

## Facts

| Field | Value |
| --- | --- |
| Citations | 49,269 |
| Field | Breast Cancer Treatment Studies |
| h-index | 118 |
| i10-index | 411 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5080832682 |
| ORCID iD | https://orcid.org/0000-0001-5913-7480 |
| Works | 964 |

## Researcher papers

- [Adjuvant Trastuzumab in HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-trastuzumab-in-her2-positive-breast-cancer/)
- [Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy](https://scholariq.org/papers/measurement-of-residual-breast-cancer-burden-to-predict-survival-after/)
- [Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics](https://scholariq.org/papers/characterization-of-a-naturally-occurring-breast-cancer-subset-enriched-in/)
- [Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](https://scholariq.org/papers/pharmacogenomic-predictor-of-sensitivity-to-preoperative-chemotherapy-with/)
- [Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification](https://scholariq.org/papers/weekly-trastuzumab-and-paclitaxel-therapy-for-metastatic-breast-cancer-with/)
- [Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy](https://scholariq.org/papers/outcome-after-pathologic-complete-eradication-of-cytologically-proven-breast/)
- [Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes](https://scholariq.org/papers/invasive-lobular-carcinoma-classic-type-response-to-primary-chemotherapy-and/)
- [w4200350191](https://scholariq.org/papers/w4200350191/)
- [Docetaxel for treatment of solid tumours: a systematic review of clinical data](https://scholariq.org/papers/docetaxel-for-treatment-of-solid-tumours-a-systematic-review-of-clinical-data/)
- [Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery](https://scholariq.org/papers/identification-of-patients-with-documented-pathologic-complete-response-in-the/)
- [Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study](https://scholariq.org/papers/determination-of-oestrogen-receptor-status-and-erbb2-status-of-breast-carcinoma/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.